Sudharsan Sridharan

Granta Park
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1.

FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 10, 2024

Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors.

Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors.

Journal: mAbs
Published: September 28, 2017

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential.

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential.

Journal: Oncoimmunology
Published: September 15, 2016

A Shorter Route to Antibody Binders via Quantitative in vitro Bead-Display Screening and Consensus Analysis.

A Shorter Route to Antibody Binders via Quantitative in vitro Bead-Display Screening and Consensus Analysis.

Journal: Scientific reports
Published: June 21, 2016

Length-independent structural similarities enrich the antibody CDR canonical class model.

Length-independent structural similarities enrich the antibody CDR canonical class model.

Journal: mAbs
Published: March 11, 2016

Overcoming the Refractory Expression of Secreted Recombinant Proteins in Mammalian Cells through Modification of the Signal Peptide and Adjacent Amino Acids.

Overcoming the Refractory Expression of Secreted Recombinant Proteins in Mammalian Cells through Modification of the Signal Peptide and Adjacent Amino Acids.

Journal: PloS one
Published: February 19, 2016

Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.

Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.

Journal: mAbs
Published: December 09, 2014

Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity.

Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity.

Journal: mAbs
Published: November 22, 2013

Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena.

Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena.

Journal: Peptides
Published: December 05, 2012

Improved drug-like properties of therapeutic proteins by directed evolution.

Improved drug-like properties of therapeutic proteins by directed evolution.

Journal: Protein engineering, design & selection : PEDS
Published: September 04, 2012
Showing 1-10 of 10

Last Updated: 09/26/2026